Litcius/Paper detail

LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial

Erik N. Mayer, Sara M. Tolaney, M.V. Martín, Gregory A. Vidal, Luca Moscetti, K. Jhaveri, Adam Brufsky, William J. Gradishar, Andreas Schneeweiß, Naoki Niikura, AM Favret, Marcos E. Alfie, Kwang Suk Lee, Sobia Khan, M Feldman, Bann-mo Day, Linda Lam, W. Darbonne, P.D. Perez Moreno, Hope Rugo

2025Annals of Oncology11 citationsDOI

Topics & Concepts

MedicineEverolimusOestrogen receptorOncologyBreast cancerInternal medicineAntagonistEstrogen receptorSelective estrogen receptor modulatorPharmacologyCancerDiscovery and development of mTOR inhibitorsAntiestrogenClinical trialCancer researchEstrogenChemotherapyGynecologyReceptorAdvanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchEstrogen and related hormone effects
LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial | Litcius